SCHEMBL20439440

SCHEMBL20439440

CNC(COc1cc2c(cnn2C2CCCCO2)cc1Br)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.40
CYP4A11 Q02928 3/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
ATR Q13535 1/20 0.37
MAPK1 P28482 1/20 0.34
MCHR1 Q99705 8/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
KCNH2 Q12809 5/20 0.33
CMKLR1 Q99788 1/20 0.33
MCHR2 Q969V1 1/20 0.33
ACACB O00763 1/20 0.33
CYP3A4 P08684 1/20 0.32
HTR3A P46098 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20439439 0.89 CYP4F2 (0.41) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL20439391 0.88 RXRA (0.39) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL20439389 0.88 RXRA (0.39) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL680099 0.82 RXRA (0.49) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL20439382 0.73 CYP4F2 (0.41) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL22836590 0.72 RXRA (0.46) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL25417935 0.71 RXRA (0.46) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL31704480 0.71 RXRA (0.46) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL680602 0.71 ATR (0.47) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL20590847 0.71 CYP4F2 (0.57) CYP4F2CYP4A11RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018138739-A1 NOVEL ANTIESTROGENIC HETEROCYCLIC COMPOUNDS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2018-08-02 WO disclosed